CYP2C8 Is a novel target of peroxisome proliferator-Activated receptor a in human liver

Molecular Pharmacology

Volumn 89, Issue 1, 2016, Pages 154-164

  Makia, Ngome L ^a   Goldstein, Joyce A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; MESSENGER RNA; MICRORNA; MICRORNA 103; MICRORNA 107; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; RETINOID X RECEPTOR ALPHA; ROSIGLITAZONE; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; CYP2C8 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; FEMALE; GEL MOBILITY SHIFT ASSAY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER; LIVER CELL; MALE; MIDDLE AGED; MUTAGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING; YOUNG ADULT; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HEP-G2 CELL LINE; METABOLISM; TRENDS;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2C8; DRUG DELIVERY SYSTEMS; HEP G2 CELLS; HEPATOCYTES; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER; PPAR ALPHA;

EID: 84958165412     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.100255     Document Type: Article

References (52)

1. Aldridge TC, Tugwood JD, and Green S (1995) Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription. Biochem J 306:473-479.
2. Aouabdi S, Gibson G, and Plant N (2006) Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferatoractivated receptor alpha binding site within the proximal promoter of PXR. Drug Metab Dispos 34:138-144.
3. Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, and Staels B (2003a) Peroxisome proliferator-Activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem 278:32852-32860.
4. Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, Kosykh V, Fruchart JC, Guillemette C, and Staels B (2003b) The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-Activated receptor alpha and gamma target gene. J Biol Chem 278:13975-13983.
5. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297.
6. Böhlig L, Friedrich M, and Engeland K (2011) p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins. Nucleic Acids Res 39:440-453.
7. Chandra V, Huang P, Potluri N, Wu D, Kim Y, and Rastinejad F (2013) Multidomain integration in the structure of the HNF-4a nuclear receptor complex. Nature 495: 394-398.
8. Chen Y, Coulter S, Jetten AM, and Goldstein JA (2009) Identification of human CYP2C8 as a retinoid-related orphan nuclear receptor target gene. J Pharmacol Exp Ther 329:192-201.
9. Chen Y and Goldstein JA (2009) The transcriptional regulation of the human CYP2C genes. Curr Drug Metab 10:567-578.
10. Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, Murphy E, Steenbergen C, Zeldin DC, and Goldstein JA (2007) Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 35:682-688.
11. Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-173.
12. Fang HL, Strom SC, Cai H, Falany CN, Kocarek TA, and Runge-Morris M (2005) Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-Activated receptor alpha transcription factor. Mol Pharmacol 67:1257-1267.
13. Ferguson SS, Chen Y, LeCluyse EL, Negishi M, and Goldstein JA (2005) Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol 68:747-757.
14. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R (1999) Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-497.
15. Gao Y, Shen W, Lu B, Zhang Q, Hu Y, and Chen Y (2014) Upregulation of hepatic VLDLR via PPARa is required for the triglyceride-lowering effect of fenofibrate. J Lipid Res 55:1622-1633.
16. García-Martín E, Pizarro RM, Martínez C, Gutierrez-Martín Y, Pérez G, Jover R, and Agúndez JA (2006) Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. Pharmacogenomics 7:575-585.
17. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrère N, and Maurel P (2001) Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29:242-251.
18. Ghonem NS, Ananthanarayanan M, Soroka CJ, and Boyer JL (2014) Peroxisome proliferator-Activated receptor a activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology 59:1030-1042.
19. Gulick T, Cresci S, Caira T, Moore DD, and Kelly DP (1994) The peroxisome proliferator-Activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 91:11012-11016.
20. Hoque MT, Robillard KR, and Bendayan R (2012) Regulation of breast cancer resistant protein by peroxisome proliferator-Activated receptor a in human brain microvessel endothelial cells. Mol Pharmacol 81:598-609.
21. Hsu MH, Savas U, Griffin KJ, and Johnson EF (2007) Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation. Drug Metab Rev 39: 515-538.
22. Juge-Aubry C, Pernin A, Favez T, Burger AG, Wahli W, Meier CA, and Desvergne B (1997) DNA binding properties of peroxisome proliferator-Activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 59-flanking region. J Biol Chem 272:25252-25259.
23. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, and Evans RM (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771-774.
24. Klose TS, Blaisdell JA, and Goldstein JA (1999) Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 13: 289-295.
25. Lai XS, Yang LP, Li XT, Liu JP, Zhou ZW, and Zhou SF (2009) Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metab 10:1009-1047.
26. Lalloyer F and Staels B (2010) Fibrates, glitazones, and peroxisome proliferatoractivated receptors. Arterioscler Thromb Vasc Biol 30:894-899.
27. Makia NL, Amunom I, Falkner KC, Conklin DJ, Surapureddi S, Goldstein JA, and Prough RA (2012) Activator protein-1 regulation of murine aldehyde dehydrogenase 1a1. Mol Pharmacol 82:601-613.
28. Makia NL, Surapureddi S, Monostory K, Prough RA, and Goldstein JA (2014) Regulation of human CYP2C9 expression by electrophilic stress involves activator protein 1 activation and DNA looping. Mol Pharmacol 86:125-137.
29. Mattijssen F, Georgiadi A, Andasarie T, Szalowska E, Zota A, Krones-Herzig A, Heier C, Ratman D, De Bosscher K, and Qi L et al. (2014) Hypoxia-inducible lipid dropletassociated (HILPDA) is a novel peroxisome proliferator-Activated receptor (PPAR) target involved in hepatic triglyceride secretion. J Biol Chem 289:19279-19293.
30. Moffit JS, Aleksunes LM, Maher JM, Scheffer GL, Klaassen CD, and Manautou JE (2006) Induction of hepatic transporters multidrug resistance-Associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-Activated receptor alpha. J Pharmacol Exp Ther 317:537-545.
31. Palmer CN, Hsu MH, Griffin HJ, and Johnson EF (1995) Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem 270:16114-16121.
32. Pineda Torra I, Jamshidi Y, Flavell DM, Fruchart JC, and Staels B (2002) Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol 16:1013-1028.
33. Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li C, Eisenhandler R, and Carlini EJ (2005) Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 22:71-78.
34. Rakhshandehroo M, Hooiveld G, Möller M, and Kersten S (2009) Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One 4:e6796.
35. Ramaswamy G, Karim MA, Murti KG, and Jackowski S (2004) PPARalpha controls the intracellular coenzyme A concentration via regulation of PANK1alpha gene expression. J Lipid Res 45:17-31.
36. Rana R, Chen Y, Ferguson SS, Kissling GE, Surapureddi S, and Goldstein JA (2010) Hepatocyte nuclear factor 4alpha regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes. Drug Metab Dispos 38: 591-599.
37. Raucy JL, Mueller L, Duan K, Allen SW, Strom S, and Lasker JM (2002) Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther 302:475-482.
38. Roy A, Jana M, Corbett GT, Ramaswamy S, Kordower JH, Gonzalez FJ, and Pahan K (2013) Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-Activated receptor a. Cell Reports 4:724-737.
39. Schoonjans K, Staels B, and Auwerx J (1996) The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302:93-109.
40. Sérée E, Villard PH, Pascussi JM, Pineau T, Maurel P, Nguyen QB, Fallone F, Martin PM, Champion S, and Lacarelle B et al. (2004) Evidence for a new human CYP1A1 regulation pathway involving PPAR-Alpha and 2 PPRE sites. Gastroenterology 127:1436-1445.
41. Synold TW, Dussault I, and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590.
42. Thomas M, Burk O, Klumpp B, Kandel BA, Damm G, Weiss TS, Klein K, Schwab M, and Zanger UM (2013) Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-Activated receptor alpha (PPARa). Mol Pharmacol 83:709-718.
43. Totah RA and Rettie AE (2005) Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77:341-352.
44. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, Heim MH, and Stoffel M (2011) MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474:649-653.
45. Villard PH, Barlesi F, Armand M, Dao TM, Pascussi JM, Fouchier F, Champion S, Dufour C, Giniès C, and Khalil A et al. (2011) CYP1A1 induction in the colon by serum: involvement of the PPARa pathway and evidence for a new specific human PPREa site. PLoS One 6:e14629.
46. Wahli W and Michalik L (2012) PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 23:351-363.
47. Waxman DJ (1999) P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 369: 11-23.
48. Wilfred BR, Wang WX, and Nelson PT (2007) Energizing miRNA research: A review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab 91:209-217.
49. Wray J and Bishop-Bailey D (2008) Epoxygenases and peroxisome proliferatoractivated receptors in mammalian vascular biology. Exp Physiol 93:148-154.
50. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, Huso D, and Lowenstein CJ (2010) P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 107:6334-6339.
51. Zeldin DC (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276:36059-36062.
52. Zhang SY, Surapureddi S, Coulter S, Ferguson SS, and Goldstein JA (2012) Human CYP2C8 is post-Transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol Pharmacol 82:529-540.